Inactive Instrument

All News Genmab Nasdaq Copenhagen

Equities

DK0010272202

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Genmab A/S - Epcoritamab Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed, Refractory Follicular Lymphoma	07-01	AQ
Genmab A/S - Completion of Share Buy-back Program	06-28	AQ
Would you like some more inflation?	06-28
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	06-28	BU
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	06-28	GL
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	06-28	CI
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Genmab Closes DKK3.5 Billion Share Buyback Early	06-28	MT
Completion of Share Buy-back Program	06-27	GL
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma	06-27	AQ
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-27	AQ
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	06-27	MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	06-27	MT
Genmab Wins US Approval for Follicular Lymphoma Treatment	06-27	MT
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	06-27	BU
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	06-27	GL
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	06-27	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm